In the last few months, another therapeutic approach for CRSwNP has emerged, namely mepolizumab, an anti-IL-5 monoclonal antibody that regulates the eosinophil activity, decreasing the blood and tissue eosinophil counts, and it is approved for severe eosinophilic asthma (SEA), eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES) and CRSwNP [19]. The gene discussed is IL5; the disease is chronic rhinosinusitis with nasal polyps.